Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel approach to treating devastating diseases. We develop Endosomal Escape Vehicle (EEV™) therapeutics, designed for efficient intracellular delivery of proteins, peptides, and nucleic acids, overcoming limitations of traditional large and small molecule therapies. This innovative technology allows us to target previously inaccessible intracellular pathways, advancing a robust portfolio of RNA-, antibody-, and enzyme-based programs for neuromuscular, ocular, metabolic, and immunological diseases. Our lead oligonucleotide programs are in development for Duchenne muscular dystrophy, and we've partnered on a clinical-stage program for myotonic dystrophy type 1. Entrada operates with a strong tech foundation, utilizing technologies such as Drupal 10, Akamai EdgeWorkers, and BunnyCDN Header for our web infrastructure and various other technologies for streamlining internal processes. Our engineering culture fosters collaboration and innovation, valuing a balance between cutting-edge technology and patient-focused results. We pride ourselves on our values of Humanity, Tenacity, Creativity, Collaboration, and Curiosity – these principles guide our work and interactions. We're a dynamic team of experts in therapeutic development and rare diseases, currently employing 101-250 people and headquartered in Boston, MA. With significant funding secured and a growing pipeline of promising therapies, Entrada is poised for continued growth and expansion. We offer a variety of remote work opportunities and employee benefits designed to support a positive work-life balance. Entrada is an equal opportunity employer committed to fostering a diverse and inclusive workplace. We encourage candidates from all backgrounds to apply.